Dr. van de Winkel is a cofounder of Genmab and served as President, Research & Development and Chief Scientific Officer of the company until his appointment as President & Chief Executive Officer in 2010. Dr. van de Winkel has more than 25 years of experience in the therapeutic antibody field and served as Vice President and Scientific Director of Medarex Europe prior to Genmab. He is the author of over 300 scientific publications and has been responsible for over 150 patents and pending patent applications. Dr. van de Winkel holds a professorship of immunotherapy at Utrecht University. He is chairman of the board of directors of Hookipa Pharma, and a member of the board of directors of LEO Pharma and Omega Alpha SPAC. He holds M.S. and Ph.D. degrees from the University of Nijmegen. Dr. van de Winkel is a registered manager of Genmab with the Danish Business Authority. www.genmab.com CEO Today Europe Award s 2022 - DENMARK - - 30 -
RkJQdWJsaXNoZXIy Mjk3Mzkz